

OPPI Collaborates with NIPER Hajipur to Advance Research Excellence

- ~ Investing in emerging scientific talent to strengthen India's position as a global pharmaceutical innovation hub
- ~ Strengthening Industry-Academia Collaboration to drive translational research and innovation

29th September 2026: The Organisation of Pharmaceutical Producers of India (OPPI) has announced a strategic collaboration with the National Institute of Pharmaceutical Education and Research, Hajipur to support and promote outcome-oriented pharmaceutical research in India.

As part of this initiative, OPPI will award gold and silver scholarships to two meritorious research scholars currently in their third or fourth year at NIPER Hajipur. The scholarships will be extended as research grants to support ongoing projects that demonstrate strong potential to address real-world healthcare challenges and contribute to meaningful advances in patient care. OPPI will also actively support the development of a 'Professor of Practice' framework, enabling experienced industry professionals from OPPI member companies to engage directly with students and researchers at NIPER Hajipur.

The collaboration also builds on NIPER Hajipur's focus on strengthening evidence-led healthcare research through its dedicated Centre of Excellence (CoE) for Health Technology Assessment (HTA). The Centre provides an important platform for advancing research and capacity building in HTA and supporting a deeper understanding of how health technologies can be evaluated to inform healthcare decision-making.

As part of its engagement with NIPER Hajipur, OPPI is also conducting guest lectures covering Health Technology Assessment (HTA), Health Economics and Outcomes Research (HEOR), and evidence-based healthcare decision-making. Through this initiative, subject-matter experts from OPPI member companies will deliver curated knowledge sessions, workshops and mentorship engagements for students. These interactions will provide valuable real-world insights, bridge the gap between academic research and evolving industry needs, and equip students with the practical understanding required to translate scientific discoveries into impactful healthcare solutions.

Anil Matai, Director General, OPPI, said, "India's aspiration to emerge as a global pharmaceutical innovation hub will depend not only on the strength of our research ecosystem, but also on our ability to connect scientific talent, industry expertise and real-world healthcare needs. Our collaboration with NIPER Hajipur is an effort to strengthen this critical bridge. By supporting promising researchers, facilitating exposure to industry perspectives and building capabilities in areas such as HTA and HEOR, we hope to encourage research that is both scientifically rigorous and relevant to the needs of patients and healthcare systems. This initiative is also aligned with the Government's continued focus on strengthening pharmaceutical education and research, including the recent push to establish three new NIPERs and upgrade seven existing institutions, as highlighted by the Department of Pharmaceuticals. This collaboration further builds on OPPI's longstanding commitment to advancing research and development in India, with several member companies already partnering with NIPER institutions across the country to foster innovation and talent development."

Prof. Ruckmani Kandasamy, Director, NIPER Hajipur, said, “NIPER Hajipur is delighted to collaborate with OPPI to strengthen industry–academia engagement and advance outcome-oriented pharmaceutical research. This partnership will provide our students and research scholars with valuable opportunities for research support, industry mentorship and meaningful exposure to real-world challenges and evolving industry practices. The curated knowledge sessions and engagements in areas such as Health Technology Assessment (HTA) and Health Economics and Outcomes Research (HEOR) will further strengthen their understanding of evidence-based healthcare decision-making and the translation of research into practical solutions. The partnership will also complement and strengthen NIPER Hajipur’s HTAIn–DHR activities by bringing industry perspectives, expertise and real-world insights into HTA and HEOR. We look forward to building a sustained and mutually beneficial partnership that nurtures future-ready scientific talent, encourages innovation and contributes to research that can make a meaningful difference to patients and healthcare systems.”

About OPPI

The Organisation of Pharmaceutical Producers of India (OPPI) established in 1965, represents the research-based global pharmaceutical companies in India and proudly marks 60 years of its contribution to the country’s healthcare ecosystem. OPPI has been an integral part of the healthcare journey of the country. We remain committed to supporting the nation’s healthcare objectives, putting patients at the core of all decision making and collaborating with all stakeholders to find sustainable solutions to realize the collective vision of Health for All.

Our member companies have been serving the country’s healthcare ecosystem since pre-independence and continue to remain committed to patient safety and providing quality care in the future as well. As an association, our advocacy decisions, patient commitment and work are always keeping the country first and we embody the spirit of working for ‘Bharat Ke Liye’; driven with innovation to find solutions for unmet medical needs, collaboration with Government stakeholders, and co-creation with partners coming together to address the nation’s healthcare challenges. We are committed to the Hon’ble Prime Minister Shri Narendra Modi-ji’s clarion call of ‘Jai Vigyan and Jai Anusandhan

2025-26 marks a defining chapter for OPPI – our Diamond Jubilee. Since its inception in 1965, OPPI has been the voice of the research based global pharmaceutical companies in India, advocating policies that encourage scientific innovation while ensuring that the patients are always at the centre of all decisions. OPPI’s journey has been defined not only by scientific and industrial progress but by the Power of Partnerships. The Diamond Jubilee offers an opportunity to honour our legacy, recognise our stakeholders, and work towards evolving into a global leader in healthcare. This landmark is a reaffirmation of our commitment to India’s future in healthcare.

*****END*****

For media queries, contact:

Asawari Sathaye, Senior Director, Communications and Access, OPPI
asawari.sathaye@indiaoppi.com

